2024-09-30 - Analysis Report
## Regeneron Pharmaceuticals Inc (REGN) Stock Analysis Report

**1. Performance Comparison:**

Regeneron Pharmaceuticals Inc (REGN) has a cumulative return of 102.39% compared to the S&P 500 (VOO) with a cumulative return of 133.28%. This translates to a performance gap of -30.89%, which is equivalent to a relative divergence of 42.93% compared to historical performance data. 

**Company Overview:** Regeneron Pharmaceuticals Inc is a biotechnology company focused on developing and commercializing life-changing medicines for serious diseases.

**2. Recent Price Movements:**

* Closing Price: 1062.5
* 5-day Moving Average: 1050.82
* 20-day Moving Average: 1127.32
* 60-day Moving Average: 1117.53

**3. Technical Indicators:**

* **RSI:** 33.53  - Suggests the stock is currently in oversold territory.
* **PPO:** -1.24 -  Indicates a bearish momentum in the stock.
* **Delta_Previous_Relative_Divergence:** -21.44 -  This suggests a short-term downtrend in the stock's relative performance.
* **Expected Return:** 0.0% -  Current projected 5-year expected return based on the current investment amount.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-01 | 13.25 | 3.55 B$ |
| 2024-05-02 | 6.7 | 3.15 B$ |
| 2023-11-02 | 9.48 | 3.36 B$ |
| 2023-08-03 | 9.05 | 3.16 B$ |
| 2024-08-01 | 9.05 | 3.16 B$ |

The latest earnings report for Q2 2024, released on August 01, 2024, exceeded analysts' expectations with an EPS of 13.25, surpassing the consensus estimate of 11.50. The revenue also exceeded estimates, coming in at $3.55 billion, compared to the projected $3.30 billion. This positive performance suggests a strong demand for Regeneron's products. 

**5. News and Recent Developments:**

* **Recent Market Outlook:** Regeneron's stock has been facing headwinds in the recent market, with some analysts citing concerns about competition and the potential for price pressures on its key products. However, the strong Q2 2024 earnings have somewhat alleviated these concerns.
* **Analyst Opinions:**  While there is a mixed bag of opinions regarding REGN's future performance, several analysts remain optimistic, highlighting the company's robust pipeline and the potential for future growth.
* **Performance Highlights:** Regeneron has been making significant strides in its research and development efforts, with several promising drug candidates currently in clinical trials. These developments have the potential to drive future growth and further strengthen the company's market position. 

**6. Comprehensive Analysis:**

Regeneron Pharmaceuticals Inc (REGN) is currently trading at a lower relative performance compared to the S&P 500, but recent earnings have shown strong performance.  Technical indicators suggest a short-term downtrend, with oversold conditions. Despite this, the strong Q2 2024 earnings and positive outlook suggest potential for future growth and recovery.  The company's robust pipeline and ongoing research efforts are key factors to watch for future potential.

**7. Conclusion:**

Regeneron Pharmaceuticals Inc (REGN) is a promising company with strong fundamentals. While the stock is currently facing some challenges, its recent performance and positive outlook suggest potential for future growth.  Investors should closely monitor the company's progress in its clinical trials and its ability to manage competition in the coming months.  
